JGC
TRVI icon

J. Goldman & Co’s Trevi Therapeutics TRVI Stock Holding History

J. Goldman & Co’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-900
Closed -$3.71K – 643
2024
Q4 		$3.71K Hold
900
– – ﹤0.01% 436
2024
Q3 		$3.01K Buy
+900
New +$2.67K ﹤0.01% 440

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

J. Goldman & Co's TRVI Position: Q1 2026 in Review

J. Goldman & Co reduced its Trevi Therapeutics (TRVI) stake by 47% in Q1 2026, selling an estimated $2.32M and leaving 236,959 shares worth $2.83M. The position accounts for 0.08% of the portfolio, ranked #266.

J. Goldman & Co first reported a position in TRVI in Q2 2022 and has held it in 16 quarters since. The position peaked at $7.25M in Q3 2025. 198 funds tracked by Wall St. Rank hold TRVI as of Q1 2026.

  • J. Goldman & Co held 236,959 shares of Trevi Therapeutics worth $2.83M as of Q1 2026.
  • J. Goldman & Co sold 207,398 Trevi Therapeutics shares in Q1 2026, an estimated $2.32M.
  • Trevi Therapeutics made up 0.08% of J. Goldman & Co's portfolio in Q1 2026, its #266 holding.
  • J. Goldman & Co first reported a position in Trevi Therapeutics in Q2 2022 and has held it in 16 quarters since.
  • J. Goldman & Co's Trevi Therapeutics position peaked at $7.25M in Q3 2025.
  • 198 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.